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Abstract
Background. Transforming growth factor-b1 (TGF-
b1) is the major profibrotic cytokine involved in many
renal diseases, and urinary TGF-b1 reflects intrarenal
TGF-b1 production. Urinary TGF-b1 excretion is
reported to be significantly increased in patients with
immunoglobulin A (IgA) nephropathy. The aim of the
present study was to compare the effects of losartan
and amlodipine on proteinuria, as well as on serum
and urine TGF-b1 levels in IgA nephropathy patients
with hypertension and proteinuria.
Methods. The initial 4 week washout period was
followed by 12 weeks of active treatment, in which
patients were randomized to once-daily treatment with
losartan 50 mg (group 1, ns20) or amlodipine 5 mg
(group 2, ns16). Urinary protein and TGF-b1
excretion, serum TGF-b1 and other clinical parameters
were determined at baseline and during 12 weeks of
active treatment.
Results. Both treatments controlled blood pressure
(BP) to a similar degree, and renal function and other
biochemical parameters did not change during the
study period. Urinary protein and TGF-b1 excretions
were significantly elevated in IgA nephropathy pati-
ents. Losartan significantly reduced urinary protein
(from 2.3"1.5 guday at baseline to 1.2"1.5 guday at
12 weeks, P-0.05) and urinary TGF-b1 excretion
(from 31.2"14.0 pgumg creatinine at baseline to
22.1"13.5 pgumg creatinine at 12 weeks, P-0.05). In
contrast, amlodipine had no affect on urinary protein
and TGF-b1 excretion. Both losartan and amlodipine
failed to reduce serum TGF-b1 levels.
Conclusion. Losartan and amlodipine, with similar
control of BP, showed different effects on urine protein
or TGF-b1 excretion. Whereas losartan improved
both urinary parameters, amlodipine did not. These
differences might be important for the management
of IgA nephropathy.
Keywords: amlopidine; IgA nephropathy; losartan;
proteinuria; transforming growth factor-b1
Introduction
Transforming growth factor-b1 (TGF-b1) is a pro-
fibrogenic cytokine involved in the synthesis of
extracellular matrix, decreasing its degradation and
stimulating the synthesis of integrin matrix receptors
[1]. Progressive nephropathies are characterized by the
enhanced accumulation of extracellular matrix in the
kidney, and overproduction of TGF-b1 can result in
pathological tissue fibrosis through the accumulation
of extracellular matrix proteins [2]. Many studies have
shown that TGF-b1 expression is increased in various
types of human glomerulonephritis, including dia-
betic nephropathy, lupus nephritis, human immuno-
deficiency virus nephropathy and immunoglobulin A
(IgA) nephropathy [3–5].
Treatment with blockers of angiotensin II actions,
such as angiotensin-converting enzyme (ACE) inhibi-
tors or angiotensin II receptor antagonists (ARAs),
retarded renal disease progression in humans and
ameliorated proteinuria in several models of kidney
damage [6]. Experimental animal and in vitro studies
recently have demonstrated that ACE inhibitors and
ARAs may also decrease the synthesis and secretion of
renal TGF-b1 [7,8]. In a prospective study, Campistol
et al. [9] demonstrated that losartan reduces TGF-b1
plasma levels in kidney transplant patients with
chronic allograft nephropathy, while amlodipine did
not significantly change them. Similarly, captopril
reduced TGF-b1 serum levels in patients with type 1
diabetes and overt nephropathy participating in the
Collaborative Study Captopril Trial [10]. It has been
speculated that inhibition of angiotensin II action
induced by losartan may decrease TGF-b1 production
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by the kidneys in chronic renal disease as well as reduce
the urinary protein excretion independently of its
blood pressure (BP) lowering effects.
Urinary TGF-b1 excretion reflects TGF-b1 produc-
tion in the kidney, and clinical and experimental
studies have suggested that measurement of urinary
TGF-b1 content may be a useful non-invasive pro-
cedure for the evaluation of the renal production of
this polypeptide [11]. In humans, urinary TGF-b1
excretion has been shown to be significantly increased
in patients with membranous nephropathy [12], dia-
betic nephropathy [13], crescentic glomerulonephritis
and IgA nephropathy [12].
The aim of this study was to compare the effects of
the ARA, losartan, with those of the calcium channel
blocker, amlodipine, on proteinuria, urinary TGF-b1
excretion and serum TGF-b1 levels in IgA nephropathy
patients with hypertension.
Patients and methods
Patient selection
Thirty-eight hypertensive IgA nephropathy patients with
serum creatinine -3.0 mgudl, and urine protein excretion
)1 guday were screened for enrollment.
Exclusion criteria included evidence or suspicion of dia-
betes, history of malignant hypertension, systolic BP
)210 mmHg, cerebrovascular accident, transient ischaemic
attacks or myocardial infarction within the previous 12
months, clinically significant arteriovenous conduction dis-
turbances anduor arrhythmias, unstable angina, history of
heart failure, serum potassiumP5.5 mmolul orO3.5 mmolul,
treatment with oral corticosteroids, and concomitant use of
agents that may affect BP and proteinuria except a- or
b-blockers, diuretics and nitrates. Urine and serum samples
from healthy volunteers (ns22) served as controls.
Study design
The study consisted of 1 week of screening, a 4-week washout
period and a 12-week active treatment period in which
patients were randomized to once-daily treatment with
losartan 50 mg or amlodipine 5 mg. After screening assess-
ment, current antihypertensive medications, other than a- or
b-blockers anduor diuretics, were discontinued during the
washout period. Additional antihypertensive agents other
than ACE inhibitors, ARAs and calcium channel blockers
were prescribed to achieve the goal of 125u75 mmHg during
the active treatment period. All trial medications were
administered once daily in the morning. The subject’s diets
were unchanged, with no additional sodium or protein
restriction.
The antihypertensive effects of the study medication were
evaluated by the results of the clinic BP measurements at
each out-patient visit (baseline, 4 and 12 weeks). Clinic BP
was measured with a standard mercury sphygmomanometer
and an appropriately sized cuff, and with Korotokoff phases
I and V for the systolic and diastolic values, respectively. The
means of three intermediate readings were recorded. Mean
arterial BP was calculated as the sum of one-third of the
systolic and two-thirds of the diastolic BP. Tolerability of
study treatment was assessed by monitoring spontaneous
reports of adverse experiences at each visit. All patients
provided written informed consent to participate, and the
protocol was approved by the ethics committee of our
hospital.
Measurement methods
A fasting blood sample was taken and a fresh morning
random urine collection was obtained at baseline, 4 weeks
and 12 weeks of active treatment for routine haematology,
blood chemistry, serum TGF-b1 and urinalysis evaluations.
Twenty-four hour urine collections were performed at
baseline, 4 weeks and 12 weeks of active treatment for
measurement of protein, sodium, potassium, urea excretion
and urinary TGF-b1 levels.
Urine preparation
Aliquots of validated 24 h urine collections were centrifuged
for 5 min to remove cells and particulate matter, and the
supernates were treated with 1 mM phenylmethylsulfonyl
fluoride (PMSF) and stored at 208C. Samples were thawed
rapidly and centrifuged for 5 min at 2000 r.p.m. to remove
any urates or phosphates before use for assays.
TGF-b1 assay of urine and serum samples
Urine and serum samples were analysed for TGF-b1
using a commercially available solid-phase enzyme-linked
immunosorbent assay (ELISA; Quantikine; R&D Systems,
Minneapolis, MN). To activate latent TGF-b1 into immuno-
reactive TGF-b1 detectable by the immunoassay test, we
performed an acidification and neutralization procedure
(pH 7.2–7.6). The TGF-b1 in the urine sample was activated
by incubation with 1.0 N HCl for 10 min followed by
neutralization with 1.2 N NaOHu0.5 molul HEPES buffer.
The TGF-b1 in the serum sample was activated by 2.5 N
acetic acidu10 M urea and neutralized by 2.7 N NaOHu1 M
HEPES. Urinary TGF-b1 excretion is reported per mg of
urinary creatinine to correct the variation in urine concen-
tration. TGF-b1 standard curves for urine and serum
samples were prepared using RD5I and RD6M calibrator
diluents, respectively. The minimum detectable level of
TGF-b1 with the test was 7 pguml.
Statistical analysis
All results are expressed as the mean"SD. Analysis of
variance for repeated measures and paired t-test were used
for within-group comparisons. Due to the non-normality of
the serum levels of TGF-b1 and 24 h urine data, changes
from baseline were analysed using the Wilcoxon signed-rank
test. Independent samples t-test and Mann–Whitney U-test
were used for between-treatment group comparisons.
Statistical significance was defined as a value of P-0.05
(two sided).
Controlling for a type 1 error of 5% and taking a power of
80% (type II error of 20%), 16 patients would be needed to be
recruited in each group in order to detect between-group
changes from baseline of 50%. It was decided to recruit;38
patients to allow for patients who may drop out of the study.
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Results
Patient characteristics and general parameters
Table 1 presents the baseline clinical characteristics of
the losartan and amlodipine groups. Baseline gender
distribution, age, weight and BP were similar in the
two treatment groups. In both groups, antihyperten-
sive drugs taken during the washout period were
maintained during the active treatment period. There
were no significant differences in the use of combina-
tion therapy (Ps0.95) or other antihypertensive
agents, such as b-blockers (Ps0.159), for the two
groups of patients during the whole study period
(Table 1). However, more patients were using diuretics
in the losartan group during the active study period.
Baseline urine TGF-b1 levels of the losartan- and
amlodipine-treated IgA nephropathy patients were
significantly higher than those of the normal healthy
controls (31.2"14.0 and 31.3"20.6 pgumg creatinine
vs 2.3"1.1 pgumg creatinine, respectively, P-0.05).
Baseline serum TGF-b1 levels did not differ among the
three groups.
Haematocrit, serum sodium, potassium, total pro-
tein, albumin, creatinine and uric acid did not change
significantly from baseline to the end of either treat-
ment period (Table 2). The creatinine clearance and
changes in creatinine clearance after 12 weeks of
treatment did not differ significantly between the two
treatment groups (Table 3).
Blood pressure responses to treatment
The BP measurements are summarized in Figure 1.
Twelve weeks of active treatment with losartan or
amlodipine alone or in combination with other
antihypertensive agents induced significant reductions
in BP; from baseline mean arterial BP (MAP) 103"
10 mmHg to 89"9 mmHg with losartan (P-0.01)
and from 102"9 mmHg to 89"8 mmHg with amlo-
dipine (P-0.01) after 12 weeks of treatment. Diastolic
BP was reduced from 89"9 mmHg to 77"10 mmHg
on losartan (P-0.01) and from 86"11 mmHg to
77"7 mmHg on amlodipine (P-0.01). Systolic BP
was reduced from 131"16 mmHg to 113"9 mmHg
Table 1. Baseline patient characteristics
Control (ns22) Losartan (ns20) Amlodipine (ns16)
Maleufemale 16u6 9u11 9u7
Age (years) 28.2"8.9 39.3"8.7 44.3"13.4
Weight (kg) 65.1"9.8 62.1"9.2 62.3"8.1
SBP (mmHg) 120"11 131"16 131"12
DBP (mmHg) 76"9 89"9 86"11
MAP (mmHg) 91"10 103"10 102"9
Antihypertensive medications
Washout period – b-Blockers (2) b-Blockers (2)
Thiazide diuretics (2) Loop diuretics (1)
Thiazide diuretics (2)
Active study period – a-Blockers (1) a-Blockers (1)
b-Blockers (2) b-Blockers (2)
Thiazide diuretics (8)** Loop diuretics (1)
Thiazide diuretics (3)
Urine protein (guday) 0.05"0.02 2.3"1.5* 2.1"0.7*
Ccr (mluminu1.73 m2) 111"27 63"22* 63"24*
Urine TGF-b1 (pgumg creatinine) 2.3"1.1 31.2"14.0* 31.3"20.6*
Serum TGF-b1 (nguml) 30.2"7.1 31.7"11.4 33.1"6.5
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; Ccr, creatinine clearance.
*P-0.05 vs control; **P-0.05 vs amlodipine.
Table 2. Changes in biochemical profiles following treatment
Losartan Amlodipine
Baseline 12 weeks Baseline 12 weeks
Hct (%) 39.6"4.6 39.0"3.8 39.8"5.3 38.4"4.4
Sodium (mEqul) 140"2 140"3 139"2 138"2
Potassium (mEqul) 4.3"0.3 4.2"0.5 4.2"0.5 3.9"0.2
Total protein (gudl) 6.8"0.5 7.0"0.3 6.8"0.3 6.8"0.3
Albumin (gudl) 4.0"0.3 4.1"0.4 4.0"0.3 3.9"0.3
Creatinine (mgudl) 1.5"0.6 1.5"0.6 1.5"0.6 1.5"0.7
Uric acid (mgudl) 6.4"1.6 6.4"1.6 7.1"1.9 6.8"2.1
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on losartan (P-0.01) and from 131"12 mmHg to
114"9 mmHg on amlodipine (P-0.01). No signifi-
cant differences with regard to the control of BP were
observed between the two treatment groups.
Effects on urine protein excretion
After 4 weeks of active treatment with losartan,
urinary protein excretion significantly decreased from
a baseline value of 2.3"1.5 gu24 h to 1.4"1.4 gu24 h
(42.7% reduction from baseline). Urine protein excre-
tion decreased further to 1.2"1.5 gu24 h at 12 weeks
(54.4% reduction from baseline) in patients on losartan
(Table 3, Figure 2). Twelve weeks of amlodipine
therapy increased urine protein excretion from a
baseline value of 2.1"0.7 gu24 h to 2.2"1.6 gu24 h
(not significant). The mean proteinucreatinine ratio of
the random urine specimen also significantly decreased
from 1.9"0.9 at baseline to 1.1"1.2 after 12 weeks of
losartan treatment (P-0.01), whereas amlodipine
treatment caused a slight increase in proteinucreatinine
ratio (from 1.7"1.1 to 2.0"1.4 after 12 weeks of
active treatment). There were no significant changes in
daily urinary sodium and potassium excretion, and
normalized protein nitrogen appearance (nPNA)
remained unchanged during the entire study period
in both treatment groups (Table 3).
Effects of treatment on urine and serum TGF-b1
Baseline urinary TGF-b1 levels did not differ between
losartan- and amlodipine-treated patients; however,
baseline urinary levels of total TGF-b1 in IgA nephro-
pathy patients were significantly greater than those of
healthy controls (Table 1). In the losartan-treated
group, urinary excretion of TGF-b1 decreased signi-
ficantly from baseline 31.2"14.0 pgumg creatinine to
23.0"12.4 pgumg creatinine after 4 weeks of treatment
(P-0.05) and was decreased further to 22.1"
13.5 pgumg creatinine at 12 weeks of active treatment
(P-0.05). Conversely, in patients treated with amlo-
dipine, urinary excretion of TGF-b1 showed no
significant change after the 12 weeks of treatment
(Figure 3). After 12 weeks of treatment, urinary
TGF-b1 levels were significantly lower in the losartan
treatment group compared with the amlodipine
treatment group (22.1"13.5 vs 29.6"19.5 pgumg
creatinine, P-0.05).
Serum levels of TGF-b1 in control subjects did not
show any significant difference when compared with
those of IgA patients receiving losartan or amlodipine
treatment (Table 1). Furthermore, serum levels of
TGF-b1 did not show any significant changes during
treatment with either drug. There was no correlation
between urine and serum TGF-b1 levels.
Table 3. Changes in urine parameters following treatment
Losartan Amlodipine
Baseline 4 weeks 12 weeks Baseline 4 weeks 12 weeks
UNa (mEquday) 198"50 199"55 203"55 204"58 196"58 199"54
UK (mEquday) 64"23 58"13 57"15 76"24 72"23 65"22
UPro (guday) 2.3"1.5 1.4"1.4* 1.2"1.5* 2.1"0.7 2.1"0.8 2.2"1.6
Random urine PCR 1.9"0.9 1.3"1.0 1.1"1.2* 1.7"1.1 1.9"1.2 2.0"1.4
Ccr (mluminu1.73 m2) 63"22 64"25 62"22 63"24 64"22 64"25
nPNA (gukguday) 1.3"0.3 1.2"0.2 1.2"0.3 1.2"0.3 1.2"0.3 1.2"0.2
UNa, urinary sodium excretion; UK, urinary potassium excretion; UPro, urinary protein excretion; PCR, protein creatinine ratio; Ccr,
creatinine clearance; nPNA, normalized protein nitrogen appearance; *P-0.05 vs baseline.
Fig. 1. Blood pressure responses to losartan (A) and amlodipine
(B) treatment. *P-0.05 vs baseline; circles, systolic blood pressure;
squares, diastolic blood pressure; triangles, mean arterial blood
pressure.
Fig. 2. Individual patient data for urinary protein excretion at
baseline and after treatment with losartan (A) and amlodipine (B).
NS, not significant.
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Correlation between urinary TGF-b1 excretion and
laboratory parameters
The relationship between urinary TGF-b1 excretion
and laboratory indices such as parameters of renal
function and amount of urinary protein excretion were
examined. Baseline urinary TGF-b1 excretion did not
correlate with creatinine clearance (Ps0.86, r2s0.021)
or baseline urinary protein level (Ps0.96, r2s0.121).
No significant correlation could be demonstrated
between changes in urinary TGF-b1 excretion and
changes in proteinuria (Ps0.86, r2s0.256) or BP in
losartan-treated patients.
Discussion
In the present study, we demonstrated that despite
similar control of BP with both losartan and amlodi-
pine, the effects on proteinuria and urine TGF-b1
excretion were completely different. Whereas losartan
caused a significant decrease in both proteinuria and
urine TGF-b1 excretion, amlodipine caused no signi-
ficant changes in either parameter. This different effect
on proteinuria and urinary TGF-b1 excretion could
have potential repercussions for treatment of IgA
nephropathy.
Treatment with blockers of angiotensin II actions,
such as ACE inhibitors or ARAs, retarded renal
disease progression and ameliorated proteinuria in
several models of kidney damage [6]. In patients with
renal disease, both with and without diabetes, it has
been demonstrated that losartan reduces proteinuria
to a similar extent to ACE inhibitors [3]. In patients
with proteinuric IgA nephropathy and mild renal
impairment, ACE inhibition and angiotensin II recep-
tor blockade with enalapril or irbesartan for 28 days
improved glomerular size selectivity and reduced
proteinuria [14]. Longer treatment with enalapril or
losartan also showed beneficial effects in patients with
IgA nephropathy with renal impairment and non-
selective proteinuria. Such patients responded to
therapy with improvement in protein selectivity,
decrease in proteinuria and improvement in renal
function [15]. The antiproteinuric effect of losartan has
also been demonstrated in a double-blind, cross-over
study comparing losartan with amlodipine in hyper-
tensive patients with non-diabetic nephropathy. In this
study, both losartan and amlodipine significantly
lowered BP, but only losartan significantly reduced
proteinuria after 4 weeks of treatment [16]. Our study
also demonstrated that losartan alone or with the
addition of low doses of other antihypertensive medi-
cations reduced proteinuria without significantly alter-
ing creatinine clearance in IgA nephropathy patients.
The magnitude of reduction in urinary protein excre-
tion after losartan treatment was 54.4"24.2% at 12
weeks. This improvement in proteinuria is similar to
the results of other clinical studies evaluating anti-
proteinuric effects of ACE inhibitors or ARAs, which
vary from 30 to 60% according to various series
[14,15].
Furthermore, the results of the present trial demon-
strated that losartan was significantly more effective
than amlodipine in reducing the urinary excretion of
protein. These findings are in agreement with those
reported by Holdaas and colleagues, who showed that
urinary albumin excretion was significantly decreased
in patients with non-diabetic renal disease following
4 weeks of treatment with losartan but was increased
with a comparable course of amlodipine treatment
[16]. The calcium channel blocker amlodipine docu-
mented no antiproteinuric effect despite a comparable
antihypertensive effect in this study. The renal effects
of calcium channel blockers remain controversial and
may vary among different agents depending on the
balance between direct renal actions and indirect
effects due to a reduction in systemic BP. Dihydro-
pyridine calcium channel blockers such as amlodipine
dilate both afferent and efferent arterioles, which
may increase proteinuria despite the reductions in
systemic BP [17]. Results of clinical studies on the
ability of calcium channel blockers to retard progres-
sion to renal failure have been variable and generally
less striking than those with ACE inhibitors [6].
Renal TGF-b1 expression is enhanced in patients
with IgA nephropathy, and it has been reported that
TGF-b1 plays a pivotal role in the progression of IgA
nephropathy [3]. Urine TGF-b1 excretion reflects
intrarenal production of TGF-b1 [11], and several
studies have found that urinary TGF-b1 excretion is
increased in patients with IgA nephropathy [18,19].
However, these clinical studies have not evaluated
the effects of ARAs or calcium channel blockers
on urinary TGF-b1 excretion in IgA nephropathy pati-
ents. In the present study, patients with IgA nephro-
pathy had up to 20 times higher urinary TGF-b1
excretion compared with the healthy control group. At
the end of the study, the reductions in urinary TGF-b1
excretion after ARA treatment were fairly consistent
with the data from previous experimental animal
Fig. 3. Individual patient data for urinary excretion of TGF-b1 at
baseline and after treatment with losartan (A) and amlodipine (B). In
losartan-treated patients, there was a 28% reduction (95% CI, 10–45,
Ps0.004) in urinary TGF-b1 excretion from 31.2 (95% CI, 23.7–
38.6) to 22.1 (95% CI, 14.7–27.4) pgumg creatinine. NS, not
significant.
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studies, in which ACE inhibitors and ARAs decreased
the synthesis and secretion of renal TGF-b1 [7]. The
main decrease in urinary TGF-b1 excretion occurred
within the first 4 weeks of losartan treatment, with a
small further decrease at 12 weeks. A similar improve-
ment in urinary TGF-b1 level with losartan therapy
has also been seen by Agarwal et al. [20] in patients
with diabetic and non-diabetic glomerulonephritides.
In their study, 4 weeks of add-on ARA treatment of
patients already treated with the maximal dose of
lisinopril resulted in early improvement in urinary
TGF-b1 excretion without changes in proteinuria or
BP. However, treatment with losartan failed to
normalize the urinary TGF-b1 excretion to the control
group level. Mean values of urinary TGF-b1, although
lower than at baseline, were significantly higher than
those in the control group after 12 weeks of losartan
therapy. This might have been due to production of
renal TGF-b1 via mechanisms other than angiotensin
II stimulation, such as persistent proteinuria, pre-
existing glomerular inflammation or non-strict dietary
salt restriction in our study. Other reasons for sub-
maximal response to ARA treatment might be the low
dose of losartan or short treatment duration. The
optimal antiproteinuric dose of losartan in non-
diabetic patients with nephrotic range proteinuria has
been reported to be 100 mg per day [21]. Further
studies with increased dose and longer duration are
needed to answer these questions.
Proteinuria and urine TGF-b1 excretion may also
decrease as a consequence of declining renal function
or improved glomerular permselectivity. In this study,
however, creatinine clearance did not change during
the 12 weeks of treatment with losartan. The pattern of
early urinary TGF-b1 reduction after losartan treat-
ment coincided with that of proteinuria reduction. This
finding suggests that reduction in urinary TGF-b1
excretion may reflect secondary effects of protein reduc-
tion by improved glomerular permselectivity caused
by losartan. However, baseline urinary TGF-b1 levels
did not correlate with levels of proteinuria in our
patients. In addition, the degree of reduction in urine
TGF-b1 levels after losartan treatment also did not
correlate with the degree of reduction in proteinuria.
Previous studies in diabetic nephropathy and mem-
branous glomerulonephritis reported a strong correla-
tion between increased urinary levels of TGF-b1 and
the extent of proteinuria [12,13]. However, those
studies found no relationship between change in
proteinuria and reduction in urinary TGF-b1 excre-
tion rate. In addition, other studies measuring urinary
levels of TGF-b1 in IgA nephropathy patients also
found no correlations between baseline proteinuria
and urine TGF-b1 excretion [18,19]. Furthermore,
in the present study, 20% of patients treated with
losartan showed no significant decrease in urinary
TGF-b1 excretion, while only one patient did not
respond to the antiproteinuric effect of losartan.
These findings support the presence of diverse
mechanisms involved in the stimulation of intrarenal
TGF-b1 production, such as angiotensin II [22],
proteinuria in the tubulointerstium [23] and increased
mechanical stress [24]. Therefore, it is difficult to
discern clearly whether reductions in urinary TGF-b1
excretion reflect an impairment in renal TGF-b1
synthesis or a passive effect of proteinuria reduction
by improved permselectivity.
Sharma et al. [10] showed that in patients with
diabetic nephropathy enrolled in the Captopril Col-
laborative Study Group Trial and studied at baseline
and 6 months after initiation of treatment with
captopril, ACE inhibition lowered serum TGF-b1
levels. However, proteinuric patients with IgA nephro-
pathy in our study showed similar serum TGF-b1
levels to those of the healthy control group, and both
losartan and amlodipine failed to decrease serum
TGF-b1. Because serum TGF-b1 levels reflect both
platelet-derived and circulating TGF-b1, an effect of
losartan on platelet activation or production of
TGF-b1 in other cells may have contributed [10].
Our finding that losartan is associated with a
significant reduction in urinary levels of TGF-b1
suggests that ARAs may provide renal protection by
blocking the production of renal TGF-b1. However,
due to the short observation period and lack of
correlation with proteinuria reduction, which is a well
known predictor of renoprotection, there is uncer-
tainty regarding the long-term renoprotective effects
of urinary TGF-b1 reduction per se. Whether ARA-
induced reduction in urinary TGF-b1 excretion is
associated with long-term renal protection requires
larger and longer prospective, randomized controlled
trials. Because we did not observe complete reduc-
tions in proteinuria and urine TGF-b1 excretions, it
remains unclear whether an even higher dose of an
ARA would produce further reductions in urinary
TGF-b1 excretion.
In summary, the present study demonstrated that
losartan and amlodipine were highly effective in the
control of hypertension in proteinuric IgA nephro-
pathy patients with hypertension. Whereas losartan
treatment significantly reduced both proteinuria
and urine TGF-b1 excretion, amlodipine increased
proteinuria and was without effect on urine TGF-b1
despite similar BP reductions. These differences might
be important for the management of proteinuric
IgA nephropathy patients with mild to moderate
hypertension.
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